Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say

Eli Lilly and Co (NYSE:LLY) on Thursday reported first-quarter earnings and lowered its 2025 guidance. The U.S. pharma giant reported January-March revenue of $12.73 billion, up 45% year over year and almost in line with the consensus of $12.67 billion. That was driven by a 53% increase in volume,…